Merck Serono S.A.
Records under this name other than the patents Merck Serono S.A. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 31 patents it holds.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 10,555,934 | Alpha-Amino Esters of Hydroxypropylthiazolidine Carboxamide Derivative and Salt Form, Crystal Polymorph Thereof Formerly held In force · High confidence | In force | High confidence | |
| US 11,524,003 | Alpha-Amino Esters of Hydroxypropylthiazolidine Carboxamide Derivative and Salt Form, Crystal Polymorph Thereof Formerly held In force · High confidence | In force | High confidence | |
| US 11,566,062 | Methods for modulating protein mannosylation profiles using maduramycin, narasin, or salinomycin Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 11,878,967 | Novel Crystalline Forms of 1-(4-{[6-Amino-5-(4-Phenoxy-PHENYL)-PYRIMIDIN-4-Ylamino]-METHYL}-4-Fluoro-PIPERIDIN-1-YL)-PROPENONE, Salt Forms Thereof, and Processes to Obtain Formerly held In force · High confidence | In force | High confidence | |
| US 7,713,947 | Cladribine Regimen for Treating Multiple Sclerosis Term ended Term ended Oct 16, 2026 · High confidence | Term ended | Term ended Oct 16, 2026 | High confidence |
| US 7,951,359 | Compositions and Methods for Therapy or Prevention of Chemotherapy-Induced Neuropathy Term ended Term ended Sep 28, 2026 · High confidence | Term ended | Term ended Sep 28, 2026 | High confidence |
| US 8,802,703 | Novel Arylamino N-Heteraryl Compounds as Mek Inhibitors Lapsed on the fee record Ended Aug 12, 2026 · High confidence | Lapsed on the fee record | Ended Aug 12, 2026 | High confidence |
| US 8,128,920 | Use of IL-18BP isoforms for the treatment and/or prevention of neurological inflammatory diseases Term ended Term ended Jun 2, 2026 · From the USPTO record | Term ended | Term ended Jun 2, 2026 | From the USPTO record |
| US 8,377,903 | Cladribine Regimen for Treating Multiple Sclerosis Term ended Term ended May 31, 2026 · Low confidence | Term ended | Term ended May 31, 2026 | Low confidence |
| US 7,824,907 | Expression vectors comprising the mCMV IE2 promoter Term ended Term ended May 30, 2026 · From the USPTO record | Term ended | Term ended May 30, 2026 | From the USPTO record |